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Abstract
Background: One virulence property of Borrelia burgdorferi is its resistance to innate immunity, in particular to complement-
mediated killing. Serum-resistant B. burgdorferi express up to five distinct complement regulator-acquiring surface proteins
(CRASP) which interact with complement regulator factor H (CFH) and factor H-like protein 1 (FHL1) or factor H-related
protein 1 (CFHR1). In the present study we elucidate the role of the infection-associated CRASP-3 and CRASP-5 protein to
serve as ligands for additional complement regulatory proteins as well as for complement resistance of B. burgdorferi.
Methodology/Principal Findings: To elucidate whether CRASP-5 and CRASP-3 interact with various human proteins, both
borrelial proteins were immobilized on magnetic beads. Following incubation with human serum, bound proteins were
eluted and separated by Glycine-SDS-PAGE. In addition to CFH and CFHR1, complement regulators CFHR2 and CFHR5 were
identified as novel ligands for both borrelial proteins by employing MALDI-TOF. To further assess the contributions of
CRASP-3 and CRASP-5 to complement resistance, a serum-sensitive B. garinii strain G1 which lacks all CFH-binding proteins
was used as a valuable model for functional analyses. Both CRASPs expressed on the B. garinii outer surface bound CFH as
well as CFHR1 and CFHR2 in ELISA. In contrast, live B. garinii bound CFHR1, CFHR2, and CFHR5 and only miniscute amounts
of CFH as demonstrated by serum adsorption assays and FACS analyses. Further functional analysis revealed that upon NHS
incubation, CRASP-3 or CRASP-5 expressing borreliae were killed by complement.
Conclusions/Significance: In the absence of CFH and the presence of CFHR1, CFHR2 and CFHR5, assembly and integration
of the membrane attack complex was not efficiently inhibited indicating that CFH in co-operation with CFHR1, CFHR2 and
CFHR5 supports complement evasion of B. burgdorferi.
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Introduction
Lyme disease is the most commonly reported vector-borne
infectious disease in Eurasia and the United States. This multi-
systemic inflammatory disease is caused by species of the Borrelia
burgdorferi sensu lato complex, which includes B. burgdorferi sensu
stricto (s.s.), B. garinii, and B. afzelii [1]. More recently, B. spielmanii
has also been shown to be associated with cutaneous manifesta-
tions of Lyme disease [2–6]. Bacteria are transmitted to humans or
other vertebrates through the bites of infected Ixodes spp. ticks. In
most cases, human infection results in a localized skin rash
accompanied by headache, myalgia, arthalgia, and fever, which
usually resolve spontaneously. Untreated Lyme disease may lead
to late manifestations that can include chronic arthritis, neurolog-
ical abnormalities, cardiac complications, and skin lesions. The
ability of Lyme disease borreliae to perpetuate their natural
vertebrate-tick infectious cycle requires an array of strategies to
survive in diverse host environments, and necessitates mechanisms
to overcome innate and adaptive immune responses of several
hosts. Lyme disease spirochetes are highly resistant to killing by the
host’s alternative pathway of complement [7,8]. This is accom-
plished, at least in part, by the spirochetes camouflaging their
outer surface with host-derived complement factor H (CFH) and
factor H-like protein 1 (FHL1) which are fluid-phase immune
regulators of the alternative complement pathway [9–12].
CFH and FHL1 are both encoded by the human CFH gene and
are derived by alternative splicing [13–15]. The two proteins are
structurally-related and fold into repetitive protein domains
termed short consensus repeats (SCRs) [14,15]. The SCRs, also
termed as complement control protein modules are approximately
60 amino acids long and contain mainly beta-sheet structures
which are stabilized by two conserved disulphide bridges. CFH is a
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FHL1 is a 42 kDa glycoprotein, comprised of the seven amino-
terminal SCRs of CFH plus four unique amino acids at the C-
terminus. Both CFH and FHL1 act as cofactors for factor I-
mediated degradation of C3b and support the dissociation (decay-
accelerating activity) of the C3 convertase, C3bBb [14]. The
human CFH family also includes six ‘‘factor H-related’’ proteins
(CFHR1, CFHR2, CFHR3, CFHR4A, CFHR4B, and CFHR5)
[16,17]. These proteins are all encoded by distinct genes, and
individual domains show extensive sequence similarities to CFH
[13]. The SCR domains toward the C-terminus of CFHR proteins
share high degrees of similarity to the C-terminal surface binding
region of SCRs 18–20 of CFH. This similarity suggests related and
conserved function(s) [12]. The human CFHR1 protein consists of
five SCRs and exists in two glycosylated forms, the 37-kDa
CFHR1a and the 43-kDa CFHR1b protein [18,19]. CFHR1 is a
complement regulator that blocks C5 convertase activity as well as
assembly and membrane insertion of the terminal components
[20]. CFHR2 is composed of four SCRs and is found in plasma as
a non-glycosylated 24-kDa form (CFHR2) and a glycosylated 29-
kDa form (CFHR2a) [21]. The function(s) of CFHR2 is poorly
understood. The 65-kDa CFHR5 protein is comprised of 9 SCRs
and displays cofactor activity for factor I-mediated inactivation of
C3b [16,22]. CFHR5 also inhibited the activity of the fluid phase
C3 convertase.
Lyme disease borreliae bind CFH, FHL1 and CFHR1 to their
outer membranes through surface-exposed lipoproteins, collec-
tively called ‘‘CRASPs’’ (complement regulator-acquiring surface
proteins) [11,23–27]. CRASPs are divided into three groups of
genetically unrelated genes/proteins and different B. burgdorferi s.s.
strains express different combinations of CRASP proteins. Each
protein has different relative affinity for each of the three human
immune regulators. Based on binding profile for CFH, FHL1 or
CFHR1, the borrelial CRASPs expressed by B. burgdorferi s.s. are
divided into (i) CFH and FHL1 binding proteins (BbCRASP-1 and
BbCRASP-2), and (ii) molecules that interact with CFH and
CFHR1, but not FHL1 (BbCRASP-3 to BbCRASP-5) [11,23–
25,28]. BbCRASP-1, also termed CspA, is a member of the
paralogous protein family 54 (PFam54), and is expressed by
spirochetes only during tick-to-mammal and mammal-to-tick
transmission stages, but not during persistent mammalian infection
[26,29–31]. The BbCRASP-2 molecule, which is also termed
CspZ, is encoded by a unique gene and is expressed at high levels
during mammalian infection [29,32]. BbCRASP-3, BbCRASP-4
and BbCRASP-5, also known as ErpP, ErpC and ErpA, are
closely-related members of the polymorphic erp gene family, and
are expressed throughout mammalian infection [10,27,30,33–37].
BbCRASP-3, BbCRASP-4, and BbCRASP-5 (hereafter referred
to as CRASP-3, CRASP-4 and CRASP-5) bind CFH and CFHR1
through the C-terminal SCR(s), and do not bind the FHL1
protein. In contrast, BbCRASP-1 and BbCRASP-2 (hereafter
referred to as CRASP-1 and CRASP-2) both bind to SCR-7 of
CFH, which is shared with FHL1, enabling these two borrelial
outer membrane proteins to bind both human complement
regulators. Borrelial mutants lacking CRASP-1 and CRASP-2 are
sensitive to complement-mediated killing in culture, and comple-
mentation with the CRASP-1 or CRASP-2 encoding genes (cspA
or cspZ, respectively), facilitates survival in the presence of serum
and, thus restores a serum-resistant phenotype [32,38].
All investigated serum-resistant borrelial strains so far express
the CFH/FHL1-binding CRASP-1 protein in combination with
two or three of the CFH/CFHR1-binding, CRASP-3, CRASP-4
or CRASP-5 proteins. The potential of the single CFH/CFHR1-
binding CRASP molecule for binding of additional members of
the CFH protein family and the contribution of these CRASP
proteins for complement resistance is still under debate. We first
sought to identify whether recombinant CRASP-3 or CRASP-5
bind to additional serum proteins beside CFH, CFHR1, and
plasminogen. Furthermore, we aimed to elucidate the role of these
two borrelial proteins towards complement resistance by transfor-
mation of a serum-sensitive B. garinii strain which lacks CFH-
binding CRASP proteins. The transformed borreliae were assayed
for abilities to bind human serum proteins, surface deposition of
complement activation products, and survival in the presence of
normal human serum (NHS).
In the present study we identified two additional members of the
human CFH protein family, CFHR2 and CFHR5 as novel ligands
for CRASP-3 and CRASP-5 of B. burgdorferi. Binding of CFHR1,
CFHR2, and CFHR5 to native and recombinant CRASP-3 and
CRASP-5 proteins was more pronounced than that of CFH. The
expression of either CRASP-3 or CRASP-5 in a serum-sensitive B.
garinii strain lacking all CRASP proteins had no considerable effect
on serum susceptibility suggesting that spirochetes must be able to
acquire sufficient amounts of CFH on their surface beside
CFHR1, CFHR2, and CFHR5 to survive in complement active
serum.
Results
Identification of serum proteins that bind to CRASP-3
and CRASP-5
To elucidate whether CRASP-3 and CRASP-5 bind several
human proteins, the recombinant his-tagged CRASP-3 and
CRASP-5 proteins were immobilized to magnetic beads. Follow-
ing incubation with NHS, beads were extensively washed and the
recombinant proteins along with bound serum proteins were
eluted. Eluates were separated by Glycine-SDS-PAGE and
analyzed by silver staining (Fig. 1). In the elute fraction of
CRASP-3- and CRASP-5-coupled beads, proteins with apparent
molecular mass of 180-, 55-, 37-, 32-, 29- and 24-kDa were
detected. Two additional proteins of 25- and 20-kDa were found
in the elute fraction of CRASP-3-coupled beads, while an 18-kDa
protein was detected only in the elute fraction of CRASP-5-
coupled beads. Several proteins in the 60- to 80-kDa range that
also attach to uncoated beads were excluded from further analysis.
A very faint band of 25-kDa could also be found in the control
lane. All eluted proteins were subjected to in-gel trypsin digestion
and peptides were analyzed using MALDI-TOF. Obtained
spectra were searched against the NCBI.fasta protein database
and a score .80 was defined to be significant (p,0.05). The 180-
kDa band found in both elution fractions yield a high protein score
of .300 of a number of the tryptic peptides representing the
complement regulator CFH. Peptides of the 55-kDa protein were
identified as fragments of CFHR5 and tryptic peptides of the 37-
and 32-kDa protein represented CFHR1b and CFHR1a, the two
different glycosylated forms of CFHR1 [39]. The 29- and the 24-
kDa band were identified as CFHR2a and CFHR2, respectively.
The 25-kDa and 20-kDa bands in the eluate fraction of CRASP-3-
coupled beads corresponded to CRASP-3 itself. Likewise, the 18-
kDa band in the eluate fraction of CRASP-5-coupled beads was
identified as CRASP-5. Thus, CRASP-3 and CRASP-5 bind
several members of the human CFH protein family including
CFHR1, CFHR2, and CFHR5.
Binding of human serum proteins CFH, CFHR1, CFHR2
and CFHR5 to CRASP-3 and CRASP-5
Next, binding of recombinant CRASP-3 and CRASP-5 to each
of the three human identified serum proteins was analyzed by
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ErpQ, two outer surface proteins which belong to the paralogous
Erp protein family and included as controls were immobilized
onto microtiter plates and incubated separately with purified
recombinant CFHR1, CFHR2 and CFHR5. Purified CFH served
as a control. All three CFHR proteins bound to both CRASP-3
and CRASP-5 but not to ErpX or ErpQ.
Ectopic expression of CRASP-3 and CRASP-5 in CRASP-
deficient B. garinii
While serum-resistant isolates of B. burgdorferi may express up to
five distinct CFH-binding CRASP molecules, the serum-sensitive
B. garinii strain G1 does not express any of these proteins during
laboratory cultivation [23]. Thus, B. garinii G1 represents a useful
model for functional analyses of the individual CRASP proteins. B.
garinii G1 was transformed with plasmids pCRASP-3 or pCRASP-
5 as well as with the empty shuttle plasmid pKFSS1. Transfor-
mations were confirmed by PCR amplification of the plasmids’
streptomycin resistance gene (aadA) and the CRASP-3 encoding
erpP or CRASP-5 encoding erpA gene (Fig. 3A). Strains G1/
pCRASP-3 and G1/pCRASP-5 each yielded an amplicon that
correspond to erpP or erpA, whereas the control strains G1 and G1/
pKFSS1 did not. The streptomycin resistance gene of the
recombinant plasmid was detected in all transformed, but not in
the untransformed wild-type strain G1.
CRASP-3 and CRASP-5 are surface-exposed, outer membrane
proteins of B. burgdorferi [40]. To confirm surface-exposure of these
proteins in transformed B. garinii, immunofluorescence microscopy
was conducted using live bacteria and polyclonal antibodies
specific for either CRASP-3 or CRASP-5 [40]. To avoid damage
to the fragile borrelial outer membrane, intact bacteria were
incubated with antibodies before being fixed onto glass slides and
sealed with mounting medium containing the DNA-binding dye
DAPI. Both CRASP-3 of transformed strain G1/pCRASP-3 and
CRASP-5 of strain G1/pCRASP-5 were detected on the outer
membrane (Fig. 3C). Intactness of the fragile borrelial outer
membrane was confirmed by demonstrating lack of binding of
antibodies directed against the periplasmic flagellar protein FlaB
(Fig. 3C middle panels). In contrast, permeabilized spirochetes
showed a strong staining with the same antibody (Fig. 3C, left
panels). Control strains G1 or G1/pKFSS1 lack any fluorescence
reactivity with each antiserum (data not shown). Surface
localization of CRASP-3 and CRASP-5 was examined, by
incubation of intact bacteria with proteinase K, followed by
ligand affinity blot analyses of borrelial lysates. Ligand affinity blot
analyses of protease-treated cells revealed that CRASP-3 and
CRASP-5 were susceptible to proteinase K digestion (Fig. 3D).
CFH-binding to borreliae was also analyzed for cell lysates
derived from CRASP-3 and CRASP-5 expressing transformants
and the non-expressing control strains G1 and G1/pKFSS1.
Ligand affinity blot demonstrated binding of CFH to G1/
pCRASP-3 and G1/pCRASP-5 but not G1 and G1/pKFSS1
(Fig. 3E and F, respectively). Thus, CRASP-3 and CRASP-5
exposed on the borrelial outer surface binds human CFH. This
allowed further assays for the interaction of CRASP-3 and
CRASP-5 with the CFHRs serum proteins.
Binding of human serum proteins by transformed B.
garinii
We next examined whether transformed strains G1/pCRASP-3
and G1/pCRASP-5 bind human complement regulators. Spir-
ochetes incubated in EDTA-treated NHS were washed extensively
and bound proteins were eluted. The final wash and the elute
fraction were separated by Glycine-SDS-PAGE and after transfer
to nitrocellulose, presence of CFH was analyzed by immunoblot
with a specific mAb. CRASP-3 and CRASP-5 expressing
transformants bound low amounts of CFH (Fig. 4A). In addition,
four prominent bands with an mobility or apparent mass of 43-,
37-, 29- and 24-kDa were present in elute fractions of G1/
Figure 1. Identification of CRASP-3 and CRASP-5 ligands
present in human serum. Recombinant, polyhistidine-tagged
CRASP-3 or CRASP-5 proteins were immobilized onto magnetic beads
and incubated with normal human serum. Empty beads were also
incubated under the same conditions and used as a control to identify
nonspecific binding of serum proteins. After extensive washing, bound
proteins were eluted with 100 mM glycine-HCl and the eluate fractions
were separated by Glycine-SDS-PAGE, following silver staining. Protein
bands indicated were cut from stained gels and proteins were identified
by mass spectrometry. Mobilities of molecular mass standards are
indicated to the left.
doi:10.1371/journal.pone.0013519.g001
Figure 2. CRASP-3 and CRASP-5 bind diverse complement
proteins. Binding of equimolar amounts of CFH, CFHR1, CFHR2, CFHR5
(33 mM) to immobilized CRASP-3, CRASP-5, ErpX, and ErpQ (5 mg/ml)
was analyzed by ELISA. Bound CFH or CFHR proteins were detected
with either goat CFH polyclonal antiserum or mouse CFHR1 monoclonal
antiserum (JHD 7.10), which reacts with all the three CFHRs. Data
represent the means and standard errors from three separate
experiments.
doi:10.1371/journal.pone.0013519.g002
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and transformant G1/pKFSS1 did not bind CFH and CFH-
related proteins. Based on the reactivity with the mAb VIG8
which reacts with CFH, CFHR1 and CFHR2 [41] and based on
the mobility, the 43- and 37-kDa proteins correspond the two
glycosylated forms CFHR1a and CFHR1b. Similarly, the 29- and
24-kDa bands represent the non-glycosylated and the glycosylated
form of CFHR2.
Figure 3. Characterization of B. garinii G1 transformants producing CRASP-3 or CRASP-5. (A and B) B. garinii G1 and transformed G1
strains were characterized by PCR amplification using flaB, aadA, erpP, and erpA gene-specific primers, as listed in Table 1. Both panels, left to right:
wild-type B. garinii G1, B. garinii G1 transformed with the empty cloning vector pKFSS1, B. garinii G1 transformed with either pCRASP-3 or pCRASP-5,
and purified pCRASP-3 or pCRASP-5 alone. (C) Demonstration of surface expression of CRASP-3 and CRASP-5 by transformed B. garinii G1, by indirect
immunofluoresecence microscopy of intact borrelial cells. Spirochetes were incubated with rabbit polyclonal anti-CRASP-3 or anti-CRASP-5 antisera
before fixation. Periplasmic FlaB used as control was detected by mAb L41 1C11 using fixed and unfixed cells. For counterstaining, the DNA-binding
dye DAPI were used to identify all bacteria. Slides were visualized at a magnification of 61000 using a Olympus CX40 fluorescence microscope
mounted with a DS-5Mc charge-coupled device camera (Nikon). (D) Surface localization of CRASP-3 and CRASP-5 in transformed G1/pCRASP-3 and
G1/pCRASP-5. Spirochetes were incubated with or without proteinase K, then lysed by sonication and total proteins separated by Tricine-SDS-PAGE.
CRASP-3 and CRASP-5 were identified using NHS and MAb VIG8 specific for the C-terminus of CFH by ligand affinity analysis. Flagellin (FlaB) was
detected with MAb L41 1C11 (dilution 1/1000) by Western blotting. (E and F) Synthesis of CRASP-3 (panel D) and CRASP-5 (panel E) by transformed
G1 as assessed by ligand-affinity blotting. Whole cell lysates were separated by Tricine-SDS-PAGE and transferred to nitrocellulose. The membranes
were incubated with NHS and binding of CFH to borrelial proteins was detected with mAb VIG8. Monoclonal antibody, L41 1C11, specific for the
flagellin protein FlaB, was used to show equal loading of bacterial lysates.
doi:10.1371/journal.pone.0013519.g003
Immune Evasion of Borrelia
PLoS ONE | www.plosone.org 4 October 2010 | Volume 5 | Issue 10 | e13519The identity of the bands was confirmed with mAb JHD 7.10,
which is specific for the N-terminus of CFHR1, CFHR2, and
CFHR5 but which does not react with CFH or FHL1 [42]. The
mAB JHD 7.10 identified bands of 50-, 43-, 37-, 29-, and 24-kDa
which represent CFHR1, CFHR2, and CFHR5, respectively
(Fig. 4B). Thus, CRASP-3 and CRASP-5 expressed on the surface
of live borreliae bind the human serum proteins CFHR1 and
CFHR2, CFHR5, and only miniscute amounts of CFH.
Serum proteins bound with different intensities to
transformed borrelial cells
To define the effect of NaCl on the interaction of the human
serum proteins to CRASP expressed on transformed borrelial
strains G1/pCRASP-3, G1/pCRASP-5 and G1/pKFSS1 was
assayed. To this end spirochetes were washed extensively with a
buffer containing 150 mM NaCl and cell-bound proteins were
subsequently eluted with increasing concentrations of salt
(450 mM to 1350 mM). The elute fractions were then separated
by Glycine-SDS-PAGE and after transfer to nitrocellulose, human
serum proteins were detected with a polyclonal anti-CFHR1
antiserum (Fig. 5A). Concerning G1/pCRASP-3, neither CFH
nor CFHR2 and CFHR5 could be detected in the fractions
containing increasing salt concentrations (Fig. 5A, middle panel).
In contrast, CFHR1 and CFHR2 as well as their glycosylated
forms were readily detectable in the final glycine fraction
suggesting that these serum proteins possess a stronger binding
capacity to surface-exposed CRASP-3. As depicted in Figure 5A
(right panel), the faint band of 150-kDa corresponding to CFH
detected after incubation of G1/pCRASP-5 with up to 450 mM
NaCl and which signal decreased at higher salt concentrations,
suggests that CFH is relatively loosely attached to the borrelial
surface. The 150-kDa band was also hardly visible in the
respective fractions of the control strain G1/pKFSS1, thus
argueing for a non-specific binding of CFH to the borrelial
surface. In contrast, CFHR1 was detectable in all fractions of
transformants expressing CRASP-3 or CRASP-5 even in the
highest concentration of NaCl as well as in the final glycine
fraction. CFHR2 was only detected in the final glycine fraction,
suggesting a stronger binding capacity of CFHR2 to CRASP-3
and CRASP-5. However, CFHR5 was not detected by this assay.
No CFHRs proteins were identified in the control transformed
strain G1/pKFSS1 (Fig. 5A, left panel).
Employing flow cytometry for analyzing binding of CFH to
G1/pKFSS1, G1/pCRASP-3, and G1/pCRASP-5, this comple-
ment regulator was bound to some extent to the surface of the
CRASP expressing strains but not to the control strain (Fig. 5B).
Taken together, binding of CFHR1 and CFHR2 to borrelial cells
expressing CRASP-3 and CRASP-5 was more pronounced than
that of CFH and CFHR5.
Serum susceptibility of B. garinii producing CRASP-3 or
CRASP-5
Having demonstrated binding of CFHRs to intact borrelial
cells, the role of CFHR for complement resistance was assayed
under more physiological conditions. B. garinii strain G1 is sensitive
to complement and does not survive in NHS while wild-type B.
burgdorferi LW2 resist complement-mediated killing and survives
even in high concentrations of NHS [7,43]. Therefore, survival
and growth of CRASP-3 and CRASP-5 expressing spirochetes in
NHS was assayed. Neither of the CRASP-3 or CRASP-5
expressing transformants grew in the presence of NHS (Fig. 6D
and E) suggesting that binding of CFHR1, CFHR2, and CFHR5
alone is not sufficient for complement resistance. The serum-
resistant strain LW2 grew equally well in medium supplemented
with NHS or heat-inactivated NHS (Fig. 6A) while both isolates
G1 and G1/pKFSS1 survived only when heat-inactivated NHS
was used (Fig. 6B and C).
Next deposition of complement activation products was
analyzed on the bacterial surface. Following incubation in NHS,
the two transformed strains G1/pCRASP-3 and G1/pCRASP-5
as well as G1/pKFSS1 and the wild-type strain G1 showed surface
deposition of C3, C6 and C5b-9 (Fig. 7). Furthermore, extensive
bleb formation and lack of DAPI staining suggests that cells are
lysed. In contrast, bacteria incubated with heat-inactivated NHS
did not show evidence of complement deposition.
To exclude that misfolding of the exogenously expressed
CRASP-3 and CRASP-5 by B. garinii, similar analyses were
performed in a B. burgdorferi mutant strain, B313. This derivative of
strain B31 expresses only CRASP-5 and lacks all other CRASP-
encoding genes. Again strain B313 was transformed with
Figure 4. Binding of serum molecules by B. garinii transfor-
mants. B. garinii strains G1, G1/pKFSS1, G1/pCRASP-3, and G1/pCRASP-
5 were incubated in NHS plus EDTA to prevent complement activation,
washed extensively, and then bound proteins were eluted using 0.1 M
glycine (pH 2.0). Both the last wash (w) and the eluate (e) fractions
obtained from each strain were separated by Glycine-SDS-PAGE and
transferred to nitrocellulose. Membranes were probed with either (A)
MAb VIG8, which recognizes the C-terminus of CFH and CFHR proteins,
or (B) mAb JHD 7.10, which recognizes CFHR1 and CFHR2, but not CFH.
Probable identities of protein bands (confirmed by data shown in Fig. 1)
are indicated to the right of each panel. Mobilities of molecular mass
standards are shown to the left of the panels.
doi:10.1371/journal.pone.0013519.g004
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NHS (data not shown).
Taken together, binding of CFHRs by CRASP-3 or CRASP-5
producing borreliae does not protect spirochetes from comple-
ment-mediated killing.
Detection of C3b inactivation products after incubation
of Borrelia with CFH
As CFH is loosely bound to CRASP-3- and CRASP-5 positive
cells, we aimed to analyze if this residual CFH can inhibit
alternative pathway activity and promote factor I-mediated C3b
inactivation. Transformed borreliae G1/pCRASP-3 and G1/
pCRASP-5, as well as G1/pKFSS1, B. garinii G1 and B. burgdorferi
s.s. LW2 (control) were first incubated with purified CFH, and
after washing factor I and C3b were added. Following incubation
for 60 min, aliquots were subjected to Glycine-SDS-PAGE, and
C3b cleavage products were detected by Western blotting. CFH
retained cofactor activity when bound to B. burgdorferi s.s. LW2 as
demonstrated by the appearance of C3b inactivation products
a’68, a’46 and a’43 kDa (Fig. 8). In contrast, none of the B. garinii
strains preincubated with CFH promoted cleavage of C3b in the
presence of factor I, suggesting that CFH was unable to maintain
its regulatory activity or extremely low amounts of C3 cleavage
products were generated.
Discussion
B. burgdorferi employs multiple strategies to survive in and
persistent in the human host. One central immune evasion
strategy is the ability of borreliae to camouflage their surface with
host fluid phase complement regulators, CFH and FHL1 [10–
12,33]. This strategy allows the spirochetes to control, inhibit and
finely regulate complement activation directly on the surface.
Figure 5. Serum proteins display differential binding capabilities to CRASP-3 and CRASP-5. (A) The binding capabilites of serum proteins
to B. garinii strains G1/pKFSS1, G1/pCRASP-3, and G1/pCRASP-5 were assessed in the presence of increasing salt concentrations. Spirochetes were
incubated in NHS plus EDTA, washed fourfold with PBSA containing 0.05% Tween20. Cells were then resuspended in PBSA containing 450 mM NaCl,
incubated for 15 min at room temperature, and sedimented by centrifugation. The steps were repeated with increasing concentrations of NaCl.
Strong binding proteins were finally eluted using 0.1 M glycine buffer (e). The supernatants obtained from the last wash fraction (150 mM NaCl),
fractions from the incubation reactions (450, 750, 1050, 1350 mM NaCl), and the eluate fraction were then separated by Glycine-SDS-PAGE and
transferred to nitrocellulose. Membranes were probed with polyclonal anti-CFHR1 antiserum to detect CFH and CFHR proteins. Mobilities of
molecular mass standards are shown to the left of the panels. (B) The binding capability of CFH to G1/pCRASP-3 and G1/pCRASP-5 was further
analyzed by flow cytometry. The binding of CFH to G1/pCRASP-3 and G1/pCRASP-5 is shown by the solid line while the grey shaded histogramm
represents the binding of control strain G1/pKFSS1 (control). Borrelial cells were incubated with 4 mg CFH. The x-acis shows the fluorescence on a
log10 scale and the the y-acis represents the numbers of events. The isotype control (no CFH added) has been omitted for easier visualization.
doi:10.1371/journal.pone.0013519.g005
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CRASP proteins, CRASP-3 and CRASP-5 of B. burgdorferi s.s. and
show that these two molecules bind the host immune regulators
CFHR2 and CFHR5. To our knowledge, this is the first report
which demonstrates binding of CFHR2 and CFHR5 to a human
pathogen. Native CRASP-3 and CRASP-5 also bind complement
regulator CFHR1 and both isoforms of CFHR1 and CFHR2. For
CFHR2 the CRASP-3 and CRASP-5 binding domain is likely also
located in the C-terminus as SCR4 of CFHR2 shows a high level
of sequence identity (89% on the amino acid level) to SCR19 of
CFH [13].
Purified, recombinant CRASP-3, CRASP-4, CRASP-5, and
other, closely related Erp proteins such as OspE and p21 derived
from different B. burgdorferi s.s. isolates bind human CFH
[10,27,33,34,44–47]. Here we demonstrate that CRASP-3 and
CRASP-5 expressed by genetically engineered B. garinii bind CFH
in solid-phase affinity blot experiments. However, the intact
transformed B. garinii, bind CFHR1, CFHR2 and CFHR5 and
bind CFH from human serum with low affinity (compared Fig. 4
and 5). This difference may be due the lack of two additional
distinct CFH-binding proteins, CRASP-1 and CRASP-2 in B.
garinii strains. Serum CFH has a coiled, folded-back conformation,
with the C-terminus extended and at physiological concentrations
can form dimeric or oligomeric complexes in solution [48–52].
Binding of CFH to human cells is initially mediated by the C-
terminal domains SCR19 and 20, which then leads to an uncoiling
of the protein and exposure of other CFH domains to additional
cell-surface receptors [13,53–55]. The various CRASPs may play
similar roles, with initial interaction of the C-terminus of CFH by
CRASP-3 or CRASP-5 followed by binding to internal regions
SCR5 to 7 of CFH by CRASP-1 or CRASP-2. Conceivably, the
writhing of live spirochetes may dislodge long, extended and
weakly bound CFH molecules from the bacterial surface, whereas
the much smaller serum proteins CFHR1, CFHR2, and CFHR5
Figure 6. Serum susceptibility of transformed B. garinii G1. A growth inhibition assay was used to investigate susceptibility to human serum of
B. burgdorferi s.s. strain LW2 (A), and B. garinii strains G1 (B), G1/pKFSS1 (C), G1/pCRASP-3 (D), and G1/pCRASP-5 (E). Spirochetes were incubated in
either 50% NHS (filled diamonds) or 50% heat-inactivated NHS (open diamonds) over a cultivation period of 8 days at 33uC, respectively. Color
changes were monitored by measurement of the absorbance at 562/630 nm. All experiments were performed three times in which each test was
done at least threefold with very similar results. For clarity only data from representative experiments are shown. Error bars represent 6 SD.
doi:10.1371/journal.pone.0013519.g006
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CRASP-3 and CRASP-5 to CFHR1 and CFHR2 compare to
CFH may also favor preferred binding of these molecules to
borrelial cells, even though CFH is present in a 10-fold higher
concentration in plasma than CFHR1, CFHR2 or CFHR5
[28,56]. Furthermore, CFHR1 which lacks C3-mediated cofactor
activity but inhibits C5 convertase activity and MAC assembly
might compete under physiological conditions with CFH for
CRASP-3 and CRASP-5 binding (CFHR1:CFH ratio of 0.37:1)
and thus reduce local CFH-mediated complement regulatory
activity [28,56]. Displacement of CFH by CFHR1 (using equal
molar amounts of both proteins) is accompanied with a significant
reduction of C3b degradation products as recently demonstrated
by Heinen et al. [20]. Moreover, CFH improperly bound to the
borrelial surface appears to be unable to efficiently inactivate
deposited C3b or accelerate the decay of the formed C3
convertase after activation of the complement cascade. This
might explains why no C3b cleavage products were detectable
when B. garinii producing CRASP-3 or CRASP-5 were incubated
with purified CFH or human serum (Fig. 8). It is likely that
CFHR2, which exhibits sequence identities of 89% and 61% to
the C-terminal SCRs 19 and 20 of CFH, respectively, also
competes with CFH for the same binding site(s) on the two
borrelial proteins.
Figure 7. Deposition of complement components C3, C6 and C5b-9 on the surface of B. garinii G1 producing CRASP-3 or CRASP-5.
Complement components deposited on B. burgdorferi s.s. LW2 (control strain), transformants G1/pKFSS1, G1/pCRASP-3, and G1/pCRASP-5 were
detected by indirect immunofluorescence microscopy. Spirochetes were incubated with either 25% normal human serum (NHS) or heat-inactivated
NHS (hiNHS). Bound C3, C6, or C5b-9 were detected using specific antibodies against each component plus appropriate Alexa 488-conjugated
secondary antibodies. For visualization of intact spirochetes, the DNA-binding dye DAPI was used. Slides were visualized at a magnification of61000
and the data were recorded via a DS-5Mc CCD camera (Nikon) mounted on an Olympus CX40 fluorescence microscope. Panels shown are
representative of at least 20 microscope fields.
doi:10.1371/journal.pone.0013519.g007
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the microbial surface, it appears that the interactions between
CFHR1, CFHR2 and CFHR5 and CRASP-3 and CRASP-5
proteins are not adequate to sufficiently protect borreliae against
complement-mediated killing (Fig. 6). This may explain why these
bacteria accumulated lethal complement activation products [C3,
C6 and C5b-9 (MAC)] on their surfaces (Fig. 7). Once complement
is activated by the borreliae, it seems that the inhibitory activity of
CFHR1 on the C5 convertase and the cofactor activity for factor I-
mediated inactivation of C3b by CFHR5 can not completely retard
formation and insertion of the MAC pointing to an crucial role of
human CFH in complement resistance of borreliae. However,
preincubation of borreliae with purified CFHR1 before treatment
of the spirochetes with complement active CFH-depleted serum did
not enhance survival of the transformants indicating that CFHR1
alone cannot restore the complement inhibitory function of CFH
(data not shown). Thus, human CFH plays a major role in evading
complement attack of B. burgdorferi.
CFHR1 and CFHR5 and likely also CFHR2 have complement-
regulatory activities, thus surface recruitment of these host proteins
may help Borrelia to control complement activation. Apparently the
three CFHR proteins alone are not sufficient to control
complement activation at the surface of Borrelia. Most likely the
CFHR proteins cooperate with CFH. CFHR1 and CFHR2 are
major constituents of serum lipoprotein particles that also contain
phospholipids, apolipoprotein A-I, lipopolysaccharide-binding
protein, and fibrinogen [57,58]. Thus, it is possible that Lyme
disease borreliae capture CFHRs or lipoprotein particles to allow
adherence to host epithelial cells and tissues, as recently described
for CFH-coated S. pneumoniae [59].
Brooks et al. reported that a B31 mutant strain carrying two
native copies of the erpA gene, but lacking the CRASP-1 encoding
cspA, displayed a serum-sensitive phenotype [60]. That result
hinted that expression of only CRASP-3 and CRASP-5 does not
sufficiently protect Lyme disease borreliae from complement-
mediated killing. However, in another report, when B. garinii strain
50/97 was genetically modified to produce the OspE protein of B.
burgdorferi s.s. strain 297 (a homolog of strain B31 CRASP-3 and
CRASP-5), those bacteria survived in the presence of 40% NHS
for up to 5 h [61]. That latter result may indicate that the strain
297 OspE protein is functionally different from the paralogous
CRASP-3 and CRASP-5 proteins of strain B31. Alternatively,
Alitalo et al. did not report having examined B. garinii strain 50/97
to see if it produced a CFH-binding protein(s) homologous to
CRASP-1 or CRASP-2 [61]. It is possible that, if strain 50/97
produced a CRASP-1 or CRASP-2 homolog, the ospE transfor-
mant would express both types of CFH-binding proteins on its
surface, and thereby bind CFH at levels sufficient to prevent
complement-mediated killing. Note that the current study used B.
garinii G1 and B. burgdorferi s.s. B313, both of which have been
demonstrated to lack CRASP-1 and CRASP-2 homologs.
Additional analyses of B. garinii strain 50/97, as well as production
and examination of transformed bacteria that specifically express a
CRASP-3/CRASP-5/OspE protein plus CRASP-1 or CRASP-2
will help clarify each CRASP alone and in combination.
In summary, we identified two new ligands, CFHR2 and
CFHR5 for the infection-associated CRASP-3 and CRASP-5
proteins of B. burgdorferi. In the absence of CRASP-1 and CRASP-
2, live borreliae that express CRASP-3 or CRASP-5 preferentially
bind CFHR1, CFHR2 and CFHR5 while binding of CFH was
rather weak. The capability of B. burgdorferi to interact with
different members of the CFH protein family via distinct CRASPs




The study and the respective consent documents were approved
by the ethic committee at the Johann Wolfgang Goethe-University
of Frankfurt (control number 160/10). All healthy blood donors
provided written informed consent.
Bacterial strains and culture conditions
B. burgdorferi s.s. strains B31 (tick isolate, USA) and LW2 (skin
isolate, Germany), B. garinii isolate G1 (CSF isolate, Germany)
classified by RFLP analysis as OspA serotype 6 according to
Michel et al. [4], and B. garinii transformants G1/pKFSS1, G1/
pCRASP-3 and G1/pCRASP-5 were grown at 33uC for 2 to 4
days to mid-exponential phase (1610
7 to 5610
7 spirochetes/ml) in
modified Barbour-Stoenner-Kelly (BSK) medium [23] or BSK
supplemented with streptomycin at a final concentration of 20 mg/
ml. The density of spirochetes was determined using dark-field
microscopy and a Kova counting chamber (Hycor Biomedical,
Garden Grove, CA). Escherichia coli DH5a or JM109 used for
cloning experiments and protein expression were grown at 37uCi n
yeast tryptone supplemented with appropriate antibiotics.
Human sera, polyclonal and monoclonal antibodies
Non-immune human serum (NHS) obtained from 20 healthy
human blood donors without known history of spirochetal
Figure 8. Detection of C3b inactivation products after incuba-
tion of CFH with B. garinii transformants. Factor I-mediated
conversion of C3b to iC3b was analyzed by detection of C3b cleavage
fragments after incubation of spirochetes with purified CFH. B.
burgdorferi s.s. LW2 producing all five CRASP proteins (control strain),
B. garinii G1, G1/pKFSS1, G1/pCRASP-3, and G1/pCRASP-5 were
incubated with CFH for 60 min at room temperature. After extensive
washing with PBS, C3b (10 ng/ml) and factor I (20 ng/ml) were added
and the mixture was incubated for 30 min at 37uC. For control purposes
all reactions were also performed in the absence of CFH. Subsequently,
the probes were boiled for 5 min, subjected to 12.5% Glycine-SDS-PAGE
and transferred onto a nitrocellulose membrane. The various C3b
degradation products (a’46- and a’43-kDa bands) were visualized by
Western blotting using a polyclonal goat anti-human C3 antiserum
(Calbiochem). As additional controls, reaction mixtures containing C3b
and factor I were incubated with or without purified CFH (lanes 11 and
12), respectively.
doi:10.1371/journal.pone.0013519.g008
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for anti-borrelial antibodies were combined to form the NHS pool.
For some studies, human serum samples were incubated at 56uC
for 30 min to inactivate complement.
A goat polyclonal antiserum was used to detect human CFH
(Merck Biosciences, Bad Soden, Germany and Complement
Technology, Tyler, TE). Mouse polyclonal anti-CFHR1 antibody
or mAb JHD 7.10 were used for detection of CFHR1 and CFHR2
andCFHR5 [41]. The goat anti-humanC3andC6antibodieswere
purchasedfrom Calbiochem,and the monoclonalanti-humanC5b-
9 antibody was obtained from Quidel (San Diego, CA, USA). To
detect borrelial proteins specific MAb and polyclonal antibodies
were used as follows: MAb L41 1C11 was used to recognize the
flagellar component FlaB, MAb N38 1.1 and rabbit polyclonal
antiserum aCRASP-3 was used to identify CRASP-3, and MAb
B11 and rabbit polyclonal antiserum aCRASP-5 were used to
detect CRASP-5 [27,62,63].
Expression of recombinant borrelial proteins
Generation of vectors pBLS538, pBLS527, pBLS536, and
pBLS539 producing amino-terminally polyhistidine-tagged
CRASP-3(ErpP), CRASP-5(ErpA), ErpQ, and ErpX, respectively
were described previously [64]. Note that the CRASP-3 and
CRASP-5 encoded by erpP and erpA of B. burgdorferi s.s. type strain
B31 and the European B. burgdorferi s.s. strain LW2 are identical.
Expression of recombinant proteins was induced in DH5a at an
OD600 of 0.6 by the addition of 0.2 mM IPTG. Following
incubation for 4 h at room temperature, cells were centrifuged
(50006g, 20 min, 4uC) and subsequently suspended in lysis buffer
(300 mM NaCl, 56 mM NaH2PO4 pH 8, 10 mM imidazole)
containing 50 mg/ml lysozyme. Cells were lysed by 6 rounds of
sonication for 30 sec using a Branson B-12 sonifier (Heinemann,
Schwa ¨bisch Gmu ¨nd, Germany). After centrifugation (14,0006g,
20 min, 4uC), supernatants were filtered through 0.45 mm filters
and stored at 220uC until used.
Expression of recombinant CFHR1, CFHR2, and CFHR5
Recombinant FHL1 and CFHR1 were expressed in Spodoptera
frugiperda Sf9 insect cells infected with recombinant baculovirus.
The cloning of various deletion constructs, expression, and
purification has been described previously [28,56,65,66].
The full length CFHR2 cDNA was cloned into pPICZaB
(Invitrogen) and the protein was expressed in the yeast Pichia
pastoris strain X33 according to standard protocols (Eberhardt et
al, manuscript in preparation). The full length CFHR5 cDNA was
cloned into pBSV-8His and expressed in the baculovirus system as
described [66] Uzonyi et al., manuscript in preparation]. All
expressed His-tagged recombinant proteins were purified by Ni
2+
chelate affinity chromatography as described [13,20].
Protein purification and serum adsorption with magnetic
beads
For protein purification of histidine-tagged proteins and
analyses of interacting serum proteins, magnetic beads (Dynabeads
TALON, Invitrogen Dynal AS, Oslo, Norway) coated with cobalt
ions were used. For purification of CRASP-3 or CRASP-5-bound
human serum proteins, E. coli lysates (1 ml) containing expressed
histidine-tagged proteins were incubated with 2 mg of magnetic
beads for 10 min at room temperature as recommend by the
manufacturer. After four washes with phosphate buffer (50 mM
phosphate, 300 mM NaCl, 0.01% Tween20), histidine-tagged
proteins coupled onto beads were incubated with NHS for 1 h at
room temperature. After extensive washing with phosphate buffer,
bound proteins were eluted with 100 mM glycine-HCl (pH 2.0)
for 15 min. The eluate and the last wash fraction were separated
by 12.5% Glycine-SDS-PAGE under non-reducing conditions
followed by staining with silver or Coomassie brilliant blue.
Sample preparation for mass spectrometry
The selected protein spots were cored from gels and subjected to
in-gel digestion protocols as described [67,68], which were
adapted for use on a MicrolabH Star digestion robot (Hamilton,
Bonaduz, Switzerland). After 12 h, the supernatant was removed
and the remaining peptides were extracted three times with 50%
(v/v) ACN/5% FA. All fractions were pooled and dried prior to
analysis. For MALDI mass spectrometric analysis the samples
were solved in 5 ml 50% ACN/1% (v/v) TFA (Fluka, Buchs,
Switzerland). 0.5 ml of the sample was mixed with 0.5 ml of matrix
(2 mg/ml a-cyano-4-hydroxycinnamic acid (Bruker, Bremen,
Germany) in 50% ACN/0.5% (v/v) TFA) directly on a stainless
steel MALDI target (Applied Biosystems (ABI), Darmstadt,
Germany) and dried under ambient conditions.
MALDI TOF MS
Delayed extraction
TM (DE) MALDI time of flight (TOF) mass
spectra were recorded on a Voyager-DE STR instrument (ABI)
using a nitrogen laser (l=336 nm, repetition rate =20 Hz) for
desorption and ionisation with an acquisition mass range from
600 m/z to 5000 m/z and the low mass gate set to 550 m/z. The
total acceleration voltage was 20 kV with 68.5% grid voltage on
the first grid, 0.02% guide wire voltage, 150 ns delay and a mirror
voltage ratio of 1.12. Spectra were externally calibrated with
Sequazyme
TM Peptide Mass Standards Kit (ABI). Between 1000
and 2000 laser shots were accumulated for each mass spectrum.
All spectra were smoothed, noise-filtered and deisotoped using
Data Explorer (Ver. 4.3, ABI). Deisotoped peaks were labelled by
the software and the 100 most intense peaks were used for
database searching. Autolytic tryptic peptides or peptides resulting
from the identified protein were used for internal calibration.
Protein database queries
Proteins were identified using Spectrum Mill (Ver. 3.0, Agilent
Technologies, Waldbronn, Germany) installed on a local server
using the MASCOT (TM) Search Engine, Matrix Science (http://
www.matrixscience.com). For PMF data, the 100 most intense peaks
weresubmitted to SpectrumMillusing asearch toleranceof 25ppm.
Construction of shuttle vectors
Vector pKFSS1, a streptomycin resistant derivative of pBSV2
[69] was used to generate shuttle vectors to allow expression of
CRASP-3 or CRASP-5 by the serum-sensitive B. garinii strain G1.
The erpP and erpA genes, plus their native promotor regions, were
amplified from B. burgdorferi s.s strain LW2 by PCR using primers
containing respective restriction sites (Table 1). The sequences of
the two erp genes of strain LW2 is identical to those of B. burgdorferi
type strain B31. Amplicons generated were digested with BamHI
and HindIII and cloned into pKFSS1 at the corresponding
restriction sites yielding shuttle vectors pCRASP-3 (expression of
CRASP-3) and pCRASP-5 (expression of CRASP-5). Purified
recombinant plasmid inserts were subjected to nucleotide
sequencing to verify that no mutations had been introduced
during PCR and cloning procedures.
Transformation of serum-sensitive B. garinii
The non-infectious, serum-sensitive B. garinii strain G1 was
grown in BSK medium and harvested at mid exponential phase
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7 to 1610
8 cells/ml). Electrocompetent cells were prepared
as described previously [70] with slight modifications. Briefly,
60 ml aliquots of competent G1 cells were electroporated at
2.5 kV/cm for 4 sec in 2-mm cuvettes with 25 mg of plasmid
DNA. Bacteria were transformed with either pCRASP-3,
pCRASP-5 or empty pKFSS1. Cells were immediately diluted
into 10 ml BSK medium and incubated without antibiotic
selection at 33uC for 48 h. For selection of transformants, cells
were diluted into 100 ml BSK medium containing 20 mg/ml
streptomycin, then 200 ml aliquots were transferred into 96-well
plates (Corning). After four to six weeks incubation at 33uC, wells
were evaluated for growth by color change of the medium and by
dark-field microscopy for the presence of motile spirochetes.
Several clones were expanded in 1 ml fresh BSK medium
containing streptomycin (20 mg/ml) for 7 to 14 days. Transformed
bacteria were then maintained in BSK medium containing 20 mg/
ml streptomycin.
PCR analysis of transformed borrelial cells
Streptomycin-resistant clones of transformed B. garinii were
characterized by PCR amplification of the introduced erpP or erpA
genes, and the recombinant plasmids’ streptomycin resistance gene
(aadA) using specific primers (Table 1). The native B. garinii flaB gene
wasalsoPCRamplifiedasapositivecontrol.Tenmicroliteraliquots
of bacterial cultures grown to mid-exponential phase were used for
direct PCR. PCR was carried out for 25 cycles using the following
parameters: denaturation at 94uC for 1 min, annealing at 50uC for
1 min, and extension at 72uC for 1 min. Reaction products were
separated by agarose gel electrophoresis, and DNA was visualized
by ethidium bromide staining and ultraviolet light.
SDS-PAGE, Western blot and ligand affinity blot analysis
Bacterial cell lysates were subjected to 10% Tricine-SDS-PAGE
under reducing conditions and samples obtained by serum
adsorption (last wash and elution fractions) were separated by
Glycine-SDS-PAGE under non-reducing conditions as previously
described [11,23]. Briefly, after transfer of proteins onto
nitrocellulose, nonspecific binding sides were blocked using 5%
(w/v) dried milk in TBS (50 mM Tris-HCl pH 7.4, 200 mM
NaCl) containing 0.1% Tween20 for 1 h at room temperature.
Subsequently, membranes were rinsed four times in TBS
containing 0.1% Tween20.
For ligand affinity blot analysis, membranes were incubated for
1 h with NHS. After four washings with TBS containing 0.2%
Tween20, membranes were incubated for 1 h with a polyclonal
rabbit antiserum that recognizes the amino-terminal regions of
CFH, monoclonal antibody (mAb) VIG8 which recognizes the C-
terminus of both CFH and CFHR1, or mAb JHD 7.10 which
recognizes CFHR1 but not CFH [20,41]. Following four washes
with TBS containing 0.2% Tween20, membranes were incubated
with an appropriate peroxidase-conjugated secondary antibody for
1 h. Detection of bound proteins was performed using 3,39,5,59-
tetramethylbenzidine (TMB) as substrate.
For Western blot analysis, membranes were incubated for 1 h at
room temperature with either mAb recognizing CRASP-3/ErpP
(N38 1.1), CRASP-5/ErpA (B11), CFH (VIG8), CFHR1 (JHD
7.10), or FlaB (L41 1C11). Following four washes with TBS
containing 0.2% Tween20, membranes were probed with
peroxidase-conjugated anti-mouse or anti-rabbit secondary anti-
body (Dako, Glostrup, Denmark) for 60 min at room temperature
and bound antibodies were detected using TMB.
ELISA
Microtiter plates (Nunc-Immuno Module) were coated with
CRASP-3 (5 mg/ml) or CRASP-5 (5 mg/ml) over night at 4uC.
The plates were washed with PBS containing 0.1% Tween20 and
treated for 1 h at RT with blocking buffer (Applichem GmBH,
Darmstadt, Germany). After washing, equimolar amounts (33 mM)
of CFH, CFHR1, CFHR2 or CFHR5 were added and incubated
for 1 h at RT. Thereafter, the wells were washed and bound CFH
or CFHR proteins were detected with either goat CFH polyclonal
antiserum or mouse CFHR1 monoclonal antiserum (JHD 7.10),
which reacts with all the three CFHRs [20]. After washing, protein
complexes were identified using appropriate secondary horserad-
ish peroxidase-coupled antiserum. The reaction was developed
with 1,2-phenylenediamine dihydrochloride (OPD, DakoCytoma-
tion, Glostrup, Denmark) and the absorbance was measured at
490 nm.
In situ protease accessibility experiments
Viable borreliae were gently washed and resuspended in 500 ml
PBS to obtained a density of 8610
5/ml. Subsequently, proteinase
K in distilled water (Sigma-Aldrich, Deisenhofen, Germany) was
added to a final concentration of 100 mg/ml. As a control, intact
Table 1. Oligonucleotides used in this study.
Oligonucleotide Sequence (59 to 39)
a Use in this work
ErpA(+) GCATTTGCAATGGATCCATTTTGGGGAGTTG cloning of erpA or erpP in pKFSS1
ErpA Hind(-) CATAATTCTTACAAGAAAGCTTCAGCGCAAAAACTGCAC cloning of erpA in pKFSS1
ErpP Hind(-) CAGCACAAACAATCAAAGCTTTTTTATTCATAATTATTC cloning of erpP in pKFSS1
CRASP-3 79(+) GATGAGCCAAAGTAGTGGTGAGATAAACC amplification of erpP gene
CRASP-3 520(-) CTATTTTAAATTTTTTTTGGATCCTTATTATGGTTTGCATA amplification of erpP gene
CRASP-5 79(+) GATGAGCAAAGCAATGGAGAGGTAAAGGTC amplification of erpA gene
ErpA 3nc (-) GTTTTTTTATTCATATACGGGCCCTCCTATATTTCTAAC amplification of erpA gene
aadA+NdeI CATATGAGGGAAGCGGTGATC amplification of aadA gene
aadR+AatII GACGTCATTATTTGCCGACTACC amplification of aadA gene
Fla6 AACACACCAGCATCGCTTTCAGGGTCT amplification of flaB gene
Fla7 TATAGATTCAAGTCTATTTTGGAAAGCACCTA amplification of flaB gene
asequences of specific restriction endonuclease recognition sites are underlined.
doi:10.1371/journal.pone.0013519.t001
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Following incubation for 2 h at room temperature, proteinase K
was terminated by adding phenylmethylsulfonyl fluoride (Sigma-
Aldrich) (50 mg/ml in isopropanol). Cells were then washed gently
twice with PBS/5 mM MgCl2, resuspended in 20 ml of the same
buffer, then lysed by sonication 5 times for 30 sec using a Branson
B-12 sonifier (Heinemann, Schwa ¨bisch Gmu ¨nd, Germany).




9 cells) grown to mid-log phase were washed
with veronal buffered saline and subsequently resuspended in
750 mM NHS supplemented with 34 mM EDTA (pH 8.0) to
avoid complement activation. After 1 h incubation at room
temperature and four washes with PBSA (0.15 M NaCl, 0.03 M
phosphate, 0.02% sodium azide, pH 7.2) containing 0.05%
Tween20, proteins bound to the cells surface were eluted with
100 mM glycine-HCl (pH 2.0) for 15 min. Cells were removed by
centrifugation at 14,0006g for 10 min at 4uC, and the supernatant
and the last wash were separated by Glycine-SDS-PAGE under
non-reducing conditions and analyzed by Western blotting as
described above.
For experiments using increasing salt concentrations, cells were
washed four times with PBSA, sedimented by centrifugation, and
resuspended in PBSA containing 450 mM of NaCl. The
spirochetes were then incubated for 15 min at room temperature,
sedimented and resuspended in PBSA containing the respective
concentration of NaCl (750 mM to 1350 mM). This procedure
was repeated for each incubation reaction. Finally, bound serum
proteins were eluted with 100 mM glycine-HCl (pH 2.0) for
15 min and all supernatants collected (last wash fraction, fractions
from the incubation reactions with increasing salt concentrations,
and the eluate fraction) were then analyzed by Western blotting
using a polyclonal anti-CFHR1 antiserum as described above.
C3b inactivation assay
The C3b cleavage capacity of B. garinii transformants was
assayed after incubation of spirochetes (4610
7) with PBS
supplemented with 750 ng/ml purified CFH for 60 min at room
temperature (Calbiochem, Darmstadt, Germany) as described
previously [43]. After washing with PBS, cells were resuspended in
50 ml PBS containing 10 ng/ml C3b (Calbiochem) and 20 ng/ml
factor I (Calbiochem) and incubated for 60 min at 37uC. Cells
were sedimented and the supernatants were mixed with sample
buffer. The samples were then subjected to Glycine-SDS-PAGE
under reducing conditions and transferred onto a nitrocellulose
membrane. C3b degradation products were detected by using
polyclonal goat anti-C3 IgG at a final dilution of 1/2000
(Calbiochem) and a secondary peroxidase-conjugated anti-goat
IgG antibody (DakoCytomation, Glostrup, Denmark). For detec-
tion, 3,39,5,59-Tetramethylbenzidine was used as substrate.
Serum susceptibility testing
Serum susceptibilities of B. garinii isolate G1, G1/pKFSS1, G1/
pCRASP-3 and G1/pCRASP-5 were assessed by growth
inhibition assay. Aliquots (1.25610
7 cells) of highly motile
spirochetes were diluted into final volumes of 100 ml fresh BSK-
medium, which contains 240 mg/ml phenol red. As bacteria grow
in BSK, the medium acidifies and the pH indicator dye turns from
red to yellow. To each aliquot of bacteria was added either 100 ml
NHS or 100 ml heat-inactivated NHS. Bacteria were then held in
96-well microtiter plates for 8 days at 33uC. For controls, aliquots
of bacteria were also incubated with 100 ml BSK medium instead
of human serum. Bacterial growth was monitored daily by
measuring the ratio of culture medium absorbance at 562 versus
630 nm using an ELISA reader (PowerWave 200; Bio-Tek
Instruments, Winooski, VT). For calculation of the growth curves
the Mikrowin Version 3.0 software (Mikrotek, Overath, Germany)
was used. Each experiment was conducted at least three times and
means 6 SD were calculated.
Flow cytometry
To analyze binding of CFH to transformed borreliae by flow
cytometry 2610
8 cells grown to mid-log phase were washed with
PBS and subsequently incubated in 300 ml PBS containing 4 mg
purified CFH (Calbiochem) for 60 min at room temperature.
Afterwards, spirochetes were washed twice and then stained with a
monoclonal anti-CFH antibody (Quidel) for 30 min at 4uC,
followed by incubation with phycoerythrin-labeld secondary
antibody (R&D, Wiesbaden, Germany) for 30 min at 4uC.
Samples were analysed immediately on a FACSCalibur (BD,
Heidelberg, Germany) using CellQuest Pro software (BD,
Heidelberg, Germany).
Immunofluorescence assay
Spirochetes grown to mid-exponential phase were harvest by
centrifugation (50006g, 30 min), washed, and resuspended in
veronal buffered saline (VBS, supplemented with 1 mM Mg
2+,
0.15 mM Ca
2+, 0.1% gelatin, pH 7.4).
For detection of deposited complement components on the
bacterial surface, spirochetes (6610
6) were incubated in 25% NHS
and, as a control, in 25% heat-inactivated NHS for 30 min at
37uC with gently agitation. After two washes with PBS containing
0.2% BSA, 10 ml aliquots of cell suspensions were spotted on glass
slides and allowed to air dry overnight. Slides were then fixed in
methanol for 10 min and air dried for 1 h. After 1 h incubation at
37uC with polyclonal antibodies directed against the complement
components C3 (1/500 dilution) (Calbiochem) or C6 (1/100
dilution) (Calbiochem) or a 1/50 dilution of a mAb directed
against C5b-9 (Quidel, San Diego, CA, USA) in a humidified
chamber, slides were gently washed four times with PBS and
subsequently incubated with a 1/2000 dilution of Alexa 488-
conjugated anti-goat antibody or Alexa 488-conjugated anti-
mouse antibody (Molecular Probes) for 1 h at 37uC.
For detecting surface-exposed proteins, polyclonal rabbit anti-
CRASP-3 antiserum (1/50 dilution) or polyclonal rabbit anti-
CRASP-5 antiserum (1/20 dilution) was added to the cells for 1 h
at 37uC with gently agitation. After two washes with PBS
containing 1% BSA, 10 ml aliquots of the cell suspensions were
spotted on glass slides and allowed to air dry overnight (= unfixed
cells). Slides were then fixed in methanol for 10 min, air dried for
1 h following the incubation with an adequate Alexa 488-
conjugated antibody. Slides were then gently washed four times
with PBS and mounted on ProLong Gold antifade reagent
(Molecular Probes) containing DAPI before being sealed. Slides
were visualized at a magnification of 61000 using a Olympus
CX40 fluorescence microscope mounted with a DS-5Mc charge-
coupled device camera (Nikon).
As a control, periplasmic FlaB was also investigated using
unfixed as well as fixed spirochetes as described previously [32].
Briefly, cells were first incubated with a 1/50 dilution of mAb L41
1C11 recognizing FlaB and washed twice with PBS containing 1%
BSA (= unfixed cells). Aliqouts of 10 ml were then spotted onto
glass slides and after air drying at room temperature, cells were
fixed with methanol. Slides were incubated with an anti-mouse
Alexa 488-conjugated antibody (1/1000 dilution), washed gently
four times with PBS, and mounted on ProLong Gold antifade
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At the same time, spirochetes were first fixed onto coverslips using
methanol and then incubated with a 1/50 dilution of mAb L41
1C11 to detected the periplasmic-located FlaB protein (= fixed
cells). The slides were then proceed as described above.
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